A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Unknown
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Keck Medicine of USC, Los Angeles, California
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
NCT01647828
Completed
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/19/2023
Locations: CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California +4 locations
Conditions: Stage IV Pancreatic Cancer
Register for Updates
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
NCT03398655
Completed
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/08/2023
Locations: UCLA-JCCC-Women's Health Clinical Research Unit, Los Angeles, California +5 locations
Conditions: Recurrent Platinum Resistant Ovarian Cancer
Register for Updates
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
NCT03214250
Completed
The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2022
Locations: University of California, Los Angeles, Los Angeles, California +2 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
NCT04132817
Completed
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response. This study utilizes an innovative clinical trial design to determine the safety, tolerability, pharmacodynamic activity and efficacy of targeting multiple, distinct combination regimens that modulate several immune and non-immune mechanisms by escalating the number of therapies administere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2022
Locations: Local Institution, Los Angeles, California +1 locations
Conditions: Breast Cancer
Register for Updates
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
Completed
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulat... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/18/2022
Locations: Kaiser Permanente-Anaheim, Anaheim, California +72 locations
Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Register for Updates
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
NCT00785291
Completed
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer. Drugs used in chemotherapy, such as paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2022
Locations: Kaiser Permanente-Anaheim, Anaheim, California +65 locations
Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
NCT03085914
Completed
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as Treatment Groups A through G below (see Study Drug and Background Therapies, Dose, and Mode of Administration). Phase 1 consisted of a 3 + 3 + 3 design intended to determine the MTD or PAD of epacadostat when given in combination with pembrolizumab and chemotherapy; effica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2022
Locations: University of California San Diego Medical Center, Moores Cancer Center, La Jolla, California +1 locations
Conditions: Solid Tumor
Register for Updates
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
NCT03086369
Completed
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2022
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +5 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Kaiser Anaheim Medical Center, Anaheim, California +66 locations
Conditions: Breast Cancer
Register for Updates
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
NCT01721746
Completed
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: UCSD Moores Cancer Center, La Jolla, California +4 locations
Conditions: Unresectable or Metastatic Melanoma
Register for Updates
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NCT03278626
Terminated
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care established by the CROSS trial: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: University of Califonia, San Diego, La Jolla, California +1 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates